Yan Li

Prof. Dr. Yan Li


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YLYao Lu
Yao Lu
WQWenke Qiu
Wenke Qiu
RLRuiWei Liao
RuiWei Liao
WCWenjuan Cao
Wenjuan Cao
FHFei fei Huang
Fei fei Huang
YLYan Li
Yan Li
Epidemiological studies prove that type II diabetes, characterized by insulin resistance (IR), may be caused by fine particulate matter 2.5 (PM2.5). However, underlying mechanisms whereby PM2.5, particularly during short-term exposure, induces liver dysfunction leading to IR remains poorly understood. In the present study, HepG2 cells and the BALB/c mouse model were used to explore how PM2.5 affects insulin sensitivity. The effects of subacute PM2.5 exposure on glucose metabolism were examined using commercial kits. Oxidative stress and inflammation were detected by fluorescent staining and RT-qPCR. The phosphorylation of PI3K/AKT was examined by Western blot. Subacute PM2.5 exposure induced IR, as reflected by increased glucose levels in cell supernatants, elevated insulin levels, and the impaired intraperitoneal glucose tolerance test in mice. PM2.5 induced oxidative stress, as evidenced by increased reactive oxygen species, cytochrome P450 2E1, and malondialdehyde, along with reduced superoxide dismutase 1/2 and silent information regulator 1. IL-6 and TNF-α were found to be upregulated using RT-qPCR. Western blot showed that PM2.5 inhibited the PI3K-AKT signaling pathway, indicated by the decreased phosphorylation of PI3K/AKT in HepG2 cells. Additionally, H&E staining showed only mild hepatic injury in mice liver. These results firmly suggest that subacute PM2.5 exposure induces insulin resistance through oxidative stress, inflammation, and the inhibition of the PI3K-AKT signaling pathway.

22 January 2022 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
LLLin Leilei
Lin Leilei
QWQiu Wenke
Qiu Wenke
LYLuo Yuyuan
Luo Yuyuan
LSLin Sihang
Lin Sihang
SXSun Xue
Sun Xue
MLMing Li
Ming Li

Verified
Journal Article
Open access
PDF file
RLRuiWei Liao
RuiWei Liao
QZQianwen Zhang
Qianwen Zhang
YLYao Lu
Yao Lu
FHFei fei Huang
Fei fei Huang
WCWenjuan Cao
Wenjuan Cao
YLYan Li
Yan Li
Fine particulate matter (PM2.5) is an environmental factor that triggers gastrointestinal diseases. However, the effects of PM2.5 on intestinal function are not fully understood. This study established an environmental exposure cell model to explore PM2.5-induced intestinal permeability alteration and its mechanisms. Intestinal barrier permeability was evaluated via trans-epithelial electrical resistance (TEER) measurement and FITC–dextran paracellular penetration analysis, followed by detection of intercellular junction protein β-catenin and its coding gene CTNNB1. Expression of inflammatory cytokines (TNF-α, IL-6) and phosphorylation of PI3K and AKT were assessed using quantitative real-time polymerase chain reaction and Western blot, respectively. Reactive oxygen species (ROS) and malondialdehyde were measured using commercial kits to observe cellular oxidative stress. The results showed that PM2.5 impaired the intestinal barrier, as indicated by reduced TEER, increased FITC–dextran penetration, down-regulated expression of β-catenin and CTNNB1. Additionally, compared with the control, inflammatory cytokines and oxidative stress markers were significantly elevated after PM2.5 exposure. The ratio of p-PI3K/PI3K and p-AKT/AKT was also up-regulated in PM2.5-exposed Caco-2 cells. Pretreatment with PI3K inhibitor LY294002 and ROS scavenger NAC modulated β-catenin expression, reduced inflammation/ROS, and alleviated the hyperpermeability of Caco-2 cells. Thus, our results reveal that PM2.5 induces PI3K/AKT-mediated inflammation and ROS generation in Caco-2 cells, leading to intestinal barrier impairment.

1 September 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
LLLin Leilei
Lin Leilei
SXSun Xue
Sun Xue
YLYan Li
Yan Li
LYLuo Yuyuan
Luo Yuyuan
WYWang Ying
Wang Ying
MLMing Li
Ming Li

29 October 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
FHFei fei Huang
Fei fei Huang
TQTang Qinghua
Tang Qinghua
KWKe Wang
Ke Wang
LZLingmei Zhou
Lingmei Zhou
RLRuiWei Liao
RuiWei Liao
MLMing Li
Ming Li
Exposure to fine particulate matter (PM2.5) poses a major threat to skin health, yet effective prevention strategies remain limited. Shikonin, a naphthoquinone derived from Lithospermum erythrorhizon, exhibits potent antioxidant and anti-inflammatory activities. However, its therapeutic application is limited by low bioavailability. To address this limitation, we developed shikonin-loaded nanoparticles (SH-NPs) using an emulsion solvent evaporation method and characterized their physicochemical properties. The protective effects of SH-NPs against PM2.5-induced skin damage were evaluated in a mouse model. The SH-NPs exhibited favorable characteristics, including a mean particle size of 209.03 ± 2.45 nm, a PDI of 0.064 ± 0.03, and a zeta potential of –17.69 ± 2.06 mV. The encapsulation efficiency is 88% and the drug loading capacity is 5.5%, respectively. In vitro, SH-NPs significantly enhanced cellular uptake in HaCaT cells. In vivo, treatment with SH-NPs significantly improved skin structural disorders, epidermal thickening, and collagen fiber reduction, while downregulating the expression of MMP-2 and MMP-9. Furthermore, SH-NPs increased the expression of SOD1 and SOD2, reduced MDA levels, and decreased the expression of TNF-α, IL-1β, and NO. In conclusion, SH-NPs attenuated PM2.5-induced skin toxicity via enhanced antioxidant, anti-inflammatory, and anti-degradation mechanisms, offering a novel strategy to boost shikonin bioavailability and prevent PM2.5-related skin damage.

Verified
Journal Article
Open access
PDF file
GCGong Chen
Gong Chen
HLHuisha Liang
Huisha Liang
BLBingxin Lu
Bingxin Lu
SDSiyuan Dai
Siyuan Dai
MLMing Li
Ming Li
LYLianbao Ye
Lianbao Ye
Non-small cell lung cancer (NSCLC) ranks among the malignancies with the highest global incidence and mortality rates. This study focused on a previous reported aniline–pyrimidine derivative, B9, which exhibited an IC50 of 21.43 μM against A549 cells. Herein, we further investigated its anti-NSCLC efficacy both in vitro and in vivo. The anti-proliferation assay proved B9 inhibits A549 cell proliferation in a concentration- and time-dependent manner, indicating B9 may have a good long-term effect in inhibiting the growth and division of cancer cells. The hemolysis assay revealed that B9 is non-hemolytic, with no observable hemolytic activity toward red blood cells, thereby confirming its preliminary biocompatibility. An in vivo efficacy study revealed that B9 effectively suppresses tumor growth within a low safe concentration of 2 μM in zebrafish models, confirming the anti-tumor efficacy of B9 was well preserved in animal models. Pharmacokinetic profiling showed B9 possesses unique metabolic profiles in rats and provides useful information of drug metabolism in vivo. Collectively, these findings establish B9 as a promising lead compound worthy of further development for NSCLC treatment.